|
1
|
Trivedi R and Mishra DP: Trailing TRAIL
resistance: Novel targets for TRAIL sensitization in cancer cells.
Front Oncol. 5:692015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thorburn A, Behbakht K and Ford H: TRAIL
receptor-targeted therapeutics: Resistance mechanisms and
strategies to avoid them. Drug Resist Updat. 11:17–24. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dai X, Zhang J, Arfuso F, Chinnathambi A,
Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: Targeting
TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural
products as a potential therapeutic approach for cancer therapy.
Exp Biol Med (Maywood). 240:760–773. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szliszka E, Mazur B, Zydowicz G, Czuba ZP
and Król W: TRAIL-induced apoptosis and expression of death
receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia
Histochem Cytobiol. 47:579–585. 2009.PubMed/NCBI
|
|
5
|
Lim B, Allen JE, Prabhu VV, Talekar MK,
Finnberg NK and El-Deiry WS: Targeting TRAIL in the treatment of
cancer: New developments. Expert Opin Ther Targets. 19:1171–1185.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen S, Fu L, Raja SM, Yue P, Khuri FR and
Sun SY: Dissecting the roles of DR4, DR5 and c-FLIP in the
regulation of Geranylgeranyltransferase I inhibition-mediated
augmentation of TRAIL-induced apoptosis. Mol Cancer. 9:232010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guancial EA, Roussel B, Bergsma DP, Bylund
KC, Sahasrabudhe D, Messing E, Mohile SG and Fung C: Bladder cancer
in the elderly patient: Challenges and solutions. Clin Interv
Aging. 10:939–949. 2015.PubMed/NCBI
|
|
9
|
Shamseddine A, Saleh A, Charafeddine M,
Seoud M, Mukherji D, Temraz S and Sibai AM: Cancer trends in
Lebanon: A review of incidence rates for the period of 2003–2008
and projections until 2018. Popul Health Metr. 12:42014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed SM, Wu X, Jin X, Zhang X, Togo Y,
Suzuki T, Li Y, Kanematsu A, Nojima M, Yamamoto S, et al:
Synergistic induction of apoptosis by mapatumumab and
anthracyclines in human bladder cancer cells. Oncol Rep.
33:566–572. 2015.PubMed/NCBI
|
|
11
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan S, Qu X, Xu L, Che X, Ma Y, Zhang L,
Teng Y, Zou H and Liu Y: Bufalin enhances TRAIL-induced apoptosis
by redistributing death receptors in lipid rafts in breast cancer
cells. Anticancer Drugs. 25:683–689. 2014.PubMed/NCBI
|
|
13
|
White-Gilbertson SJ, Kasman L, McKillop J,
Tirodkar T, Lu P and Voelkel-Johnson C: Oxidative stress sensitizes
bladder cancer cells to TRAIL mediated apoptosis by down-regulating
anti-apoptotic proteins. J Urol. 182:1178–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
LeBlanc H, Lawrence D, Varfolomeev E,
Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and
Ashkenazi A: Tumor-cell resistance to death receptor-induced
apoptosis through mutational inactivation of the proapoptotic Bcl-2
homolog Bax. Nat Med. 8:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi YL, Feng S, Chen W, Hua ZC, Bian JJ
and Yin W: Mitochondrial inhibitor sensitizes non-small-cell lung
carcinoma cells to TRAIL-induced apoptosis by reactive oxygen
species and Bcl-X(L)/p53-mediated amplification mechanisms. Cell
Death Dis. 5:e15792014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang WW, Yang JS, Pai SJ, Wu PP, Chang
SJ, Chueh FS, Fan MJ, Chiou SM, Kuo HM, Yeh CC, et al: Bufalin
induces G0/G1 phase arrest through inhibiting the levels of cyclin
Dcyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial
signaling pathway in T24 human bladder cancer cells. Mutat Res.
732:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Bufalin induces growth inhibition, cell cycle arrest
and apoptosis in human endometrial and ovarian cancer cells. Int J
Mol Med. 21:637–643. 2008.PubMed/NCBI
|
|
20
|
Yeh JY, Huang WJ, Kan SF and Wang PS:
Effects of bufalin and cinobufagin on the proliferation of androgen
dependent and independent prostate cancer cells. Prostate.
54:112–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L,
Song N, Teng Y and Liu Y: Down-regulation of Cbl-b by bufalin
results in up-regulation of DR4/DR5 and sensitization of
TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin
Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelley RF, Totpal K, Lindstrom SH, Mathieu
M, Billeci K, Deforge L, Pai R, Hymowitz SG and Ashkenazi A:
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor
necrosis factor- related apoptosis-inducing ligand reveal a greater
contribution of death receptor (DR) 5 than DR4 to apoptosis
signaling. J Biol Chem. 280:2205–2212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin XM: Signal transduction mediated by
Bid, a pro-death Bcl-2 family proteins, connects the death receptor
and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shalini S, Dorstyn L, Dawar S and Kumar S:
Old, new and emerging functions of caspases. Cell Death Differ.
22:526–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin CY, Park C, Hwang HJ, Kim GY, Choi BT,
Kim WJ and Choi YH: Naringenin up-regulates the expression of death
receptor 5 and enhances TRAIL-induced apoptosis in human lung
cancer A549 cells. Mol Nutr Food Res. 55:300–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong SH and Choi YH: Bufalin induces
apoptosis through activation of both the intrinsic and extrinsic
pathways in human bladder cancer cells. Oncol Rep. 27:114–120.
2012.PubMed/NCBI
|
|
27
|
Li Y, Jin X, Li J, Jin X, Yu J, Sun X, Chu
Y, Xu C, Li X, Wang X, et al: Expression of TRAIL, DR4, and DR5 in
bladder cancer: Correlation with response to adjuvant therapy and
implications of prognosis. Urology. 79:968.e7–e15. 2012. View Article : Google Scholar
|
|
28
|
Wu GS: TRAIL as a target in anti-cancer
therapy. Cancer Lett. 285:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Z, Sangwan V, Banerjee S, Chugh R,
Dudeja V, Vickers SM and Saluja AK: Triptolide sensitizes
pancreatic cancer cells to TRAIL-induced activation of the death
receptor pathway. Cancer Lett. 348:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Safa AR: c-FLIP, a master anti-apoptotic
regulator. Exp Oncol. 34:176–184. 2012.PubMed/NCBI
|
|
31
|
Ewald F, Ueffing N, Brockmann L, Hader C,
Telieps T, Schuster M, Schulz WA and Schmitz I: The role of c-FLIP
splice variants in urothelial tumours. Cell Death Dis. 2:e2452011.
View Article : Google Scholar : PubMed/NCBI
|
